Ublituximab has been shown to increase NK cell-mediated ADCC against CLL cells ex vivo compared to rituximab [154] and to have promising efficacy in phase 2 and/or phase 3 clinical trials either as a single agent or in combination with the BTK inhibitor ibrutinib and the next-generation PI3K inhibitor umbralisib in high-risk CLL [228,229,230]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.